Updated
Rocket PharmaceuticalsRCKT · Healthcare
$2.38-2.05%
Market cap$261M
IndustryBiotechnology
Rocket Pharmaceuticals (RCKT) Superinvestor holders
10 of the superinvestors we track hold Rocket Pharmaceuticals (RCKT) in their latest 13F filings, $49M in total.
Summary
The largest holder is Paul Marshall (Marshall Wace), with $14M, 0.0% of the portfolio.
In their latest quarter: 4 added, 3 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Paul Marshall Marshall Wace |
Added | 4,029,262 | $14M | 0.0% | Q2 2026 |
| Lee Ainslie Maverick Capital |
Added | 3,923,963 | $13M | 0.1% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 3,386,162 | $12M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 950,552 | $3M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Added | 792,974 | $3M | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
Trimmed | 670,527 | $2M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 315,761 | $1M | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
Held | 186,596 | $638,158 | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 86,000 | $294,120 | 1.4% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Held | 50,493 | $172,686 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 10 |
| Q1 2026 | 10 |
| Q4 2025 | 13 |
| Q3 2025 | 11 |
| Q2 2025 | 10 |
| Q1 2025 | 10 |
| Q4 2024 | 11 |
| Q3 2024 | 12 |
Questions about Rocket Pharmaceuticals
Which superinvestors own Rocket Pharmaceuticals?
10 of the superinvestors we track hold Rocket Pharmaceuticals (RCKT) in their latest 13F filings, $49M in total. Paul Marshall, Lee Ainslie, Cliff Asness, David Shaw, Jim Simons, Steve Cohen.
Who is the largest superinvestor holder of RCKT?
The largest holder is Paul Marshall (Marshall Wace), with $14M, 0.0% of the portfolio.
From Rocket Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.